124 related articles for article (PubMed ID: 32307567)
1. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Gao M; Zhao X
Ann Hematol; 2020 Nov; 99(11):2703-2704. PubMed ID: 32307567
[No Abstract] [Full Text] [Related]
2. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
3. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
[TBL] [Abstract][Full Text] [Related]
4. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Du Pisani LA; Shires K
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
6. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.
Miglino M; Colombo N; Grasso R; Marani C; Clavio M; Pica GM; Ballerini F; Ghiggi C; Minetto P; Guolo F; Carella AM; Gobbi M
Leuk Lymphoma; 2012 Nov; 53(11):2214-7. PubMed ID: 22475129
[TBL] [Abstract][Full Text] [Related]
8. [Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia].
Savva NN; Belevtsev MV; Savitskiĭ VP; Migal' NV; Movchan LV; Aleĭnikova OV
Klin Lab Diagn; 2009 Dec; (12):15-8. PubMed ID: 20140998
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
10. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
11. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
12. Widespread use of measurable residual disease in acute myeloid leukemia practice.
Epstein-Peterson ZD; Devlin SM; Stein EM; Estey E; Tallman MS
Leuk Res; 2018 Apr; 67():92-98. PubMed ID: 29482173
[TBL] [Abstract][Full Text] [Related]
13. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
Chen X; Cherian S
Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
[TBL] [Abstract][Full Text] [Related]
14. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu J; Jorgensen JL; Wang SA
Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
[TBL] [Abstract][Full Text] [Related]
17. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Mauvieux L; Miguet L; Fornecker L
N Engl J Med; 2018 Jun; 378(25):2442-3. PubMed ID: 29926700
[No Abstract] [Full Text] [Related]
18. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Ulrich BC
N Engl J Med; 2018 Jun; 378(25):2442. PubMed ID: 29926698
[No Abstract] [Full Text] [Related]
19. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Löwenberg B; Valk PJM
N Engl J Med; 2018 Jun; 378(25):2443. PubMed ID: 29924951
[No Abstract] [Full Text] [Related]
20. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
Dai Q; Ren Y
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
